Spinal cord injury (SCI) is a severe distressed condition which can leave lifelong disability behind. Physical destruction of neurons and blood vessel of spinal cord cause this injury. That is followed by secondary inflammation damaging tissues and forming lesions.
These secondary events associated with SCI have become a challenge and therefore, an efficient neuro-protective component is needed. Primarily corticosteroids are used in such conditions however the most effective treatment option is still being searched1.
Several other treatments are also available for spinal cord injury but they are not much effective. Each treatment has its own limitations2. One such treatment is Methylprednisolone (MP), it has been widely used in SCI inflammations3. Its anti-inflammatory effect is due to the involvement with lipocortins, which regulate the expression of prostaglandins and interleukin genes4.
Despite having high oral bioavailability the effectives of Methylprednisolone (MP) drug is low. It has very low binding power. It efficacy can be achieve by avoiding its exposure to the proteins after encapsulating it in a carrier molecule. That can improve its distribution even in the aqueous environment and administering it locally at SCI site. Also that can incorporate it inside some solid capsule which has high transference activity5.
Using lipid based nanoparticles in which encapsulate the drug so that can be one effective and improve the drug distribution6. Lipid forms a bi-layer which interrelates with biological membrane and if the size of formed particle is very less, particle interaction becomes very efficient.
In order to achieve this, researchers selected a miniature lipid particle that might ensure control release of the encapsulated drug. Lipid based solid nano-particles (MSLN) were used so that they can interact with membranes in an efficient manner and can release the MP in controlled manner6.
This dosage form can be beneficial for safer and effective mean for the treatment of post SCI like conditions and will help the researcher to uncover the critical areas of the treatment of secondary inflammations associated with SCI like conditions that previously was not been explored.
The pre-emulsification ultrasonic probe sonication method was used for preparation of MSLNs. The MSLN was characterized on the basis of entrapment efficiency, particle size, surface charge, poly-disparity index and morphological characteristics.
Authors conclusively said:
“Higher degree of protein binding leads to limited efficacy of MP when it injected to the blood circulation. It might also overcome the dose related toxicity associated with MP as this technique is achieving therapeutic level of the MP even after 10 folds reduction in its dose. Therefore, it might prove itself as a cost effective, safe, efficacious and clinically pertinent novel dosage form for the potential delivery of MP at SCI site. Further, this investigation provides an opportunity to the investigators working in the area of spinal cord injury.”
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
17 November, 2019